Patent ID: 8666762
Filing Date: 2014-03-04
Classification: G06Q,G16H

Abstract:
1. A tissue management system incorporating a database of information, processor, and software program containing an organized set of instructions for tracking the internal processing by a medical establishment of a piece of transplantable material provided by a supplier for subsequent transplantation or implantation into a patient, such system comprising: (a) means for assigning a unique identification code to the transplantable material upon its receipt by the medical establishment from the supplier; (b) means for prompting an inspection of the transplantable material upon its receipt from the supplier for an unsafe condition; (c) a comprehensive set of standard operating procedures adopted by the medical establishment covering at least one step for login, handling, storage conditions, reconstitution, or surgical use of the transplantable material by staff members of the medical establishment in a manner compliant with prevailing safety regulations and industry mandates; (d) means for entering into the database required data concerning how the at least one step for the login, handling, storage conditions, reconstitution or surgical use of the transplantable material by the staff member was carried out; (e) means for processing such entered data by the software program which is built upon the standard operating procedures to ensure that the step for the login, handling, storage conditions, reconstitution, or surgical use of the transplantable material was conducted strictly in a manner compliant with the standard operating procedures before the next step for the login, handling, storage conditions, reconstitution, or surgical use of the transplantable material can be undertaken by the staff members; (f) means for prompting the assessment of the patient after transplantation or implantation of the transplantable material for evidence of an adverse effect; (g) means for prompting the investigation of any such adverse effect discovered in the patient to determine whether it constitutes an adverse reaction; and (h) means for reporting any such adverse reaction to the supplier that supplied the transplant material to the medical establishment; (i) wherein the transplantable material is chosen from the group consisting of human cells, tissue, or organs intended for implantation, transplantation, infusion, or transfer to a patient, including, but not limited to: musculoskeletal tissues like bone, tendons, fascia, ligaments, cartilage, and bioengineered bone products; skin; cardiovascular tissues like heart valves, arteries, veins, and pericardium; reproductive cells like sperm, semen, oocytes, fertilized eggs, and embryos; cellular therapies like stem cells, progenitor cells, cord blood, chondrocytes, bone marrow, and neural cells; dura mater; breast milk; eyes, corneas; organs; islet cells; parathyroids; autologous tissue; and synthetic and xenographic tissue used as replacements for human tissue; as well as non-biologic implants, including but not limited to: titanium screws; titanium or carbon-fiber cages or resorbable cages, fixation systems, saline or silicone breast implants, synthetic polymers, prosthetic hips, knees and other joint combinations thereof; as well as surgical instruments, equipment, reagents, and supplies associated with the transplanting or implanting of any transplant material into a patient; and (j) wherein the medical establishment is an organization directed to the storage, research, transplantation, or implantation of transplantable materials chosen from the group consisting of hospitals, medical clinics, surgical centers, fertility clinics, tissue banks, organ banks, organ donor banks, university and research facilities, diagnostic laboratories, and willed body programs.